Relay Therapeutics (RLAY) Competitors $3.29 -0.04 (-1.20%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$3.27 -0.02 (-0.49%) As of 05/1/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RLAY vs. TARS, GMTX, BEAM, NAMS, KYMR, BLTE, BHC, JANX, AAPG, and ARWRShould you be buying Relay Therapeutics stock or one of its competitors? The main competitors of Relay Therapeutics include Tarsus Pharmaceuticals (TARS), Gemini Therapeutics (GMTX), Beam Therapeutics (BEAM), NewAmsterdam Pharma (NAMS), Kymera Therapeutics (KYMR), Belite Bio (BLTE), Bausch Health Companies (BHC), Janux Therapeutics (JANX), Ascentage Pharma Group International (AAPG), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry. Relay Therapeutics vs. Tarsus Pharmaceuticals Gemini Therapeutics Beam Therapeutics NewAmsterdam Pharma Kymera Therapeutics Belite Bio Bausch Health Companies Janux Therapeutics Ascentage Pharma Group International Arrowhead Pharmaceuticals Relay Therapeutics (NASDAQ:RLAY) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, community ranking, earnings and risk. Is RLAY or TARS more profitable? Relay Therapeutics has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -103.64%. Relay Therapeutics' return on equity of -45.75% beat Tarsus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Relay TherapeuticsN/A -45.75% -40.75% Tarsus Pharmaceuticals -103.64%-55.86%-39.28% Which has more volatility & risk, RLAY or TARS? Relay Therapeutics has a beta of 1.7, meaning that its stock price is 70% more volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Do analysts rate RLAY or TARS? Relay Therapeutics presently has a consensus target price of $18.36, suggesting a potential upside of 458.17%. Tarsus Pharmaceuticals has a consensus target price of $63.67, suggesting a potential upside of 26.57%. Given Relay Therapeutics' higher probable upside, research analysts clearly believe Relay Therapeutics is more favorable than Tarsus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Relay Therapeutics 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.82Tarsus Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has higher valuation and earnings, RLAY or TARS? Tarsus Pharmaceuticals has higher revenue and earnings than Relay Therapeutics. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRelay Therapeutics$10.01M55.73-$341.97M-$2.39-1.38Tarsus Pharmaceuticals$182.95M10.55-$135.89M-$3.10-16.23 Does the media prefer RLAY or TARS? In the previous week, Tarsus Pharmaceuticals had 3 more articles in the media than Relay Therapeutics. MarketBeat recorded 14 mentions for Tarsus Pharmaceuticals and 11 mentions for Relay Therapeutics. Tarsus Pharmaceuticals' average media sentiment score of 1.37 beat Relay Therapeutics' score of 0.02 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tarsus Pharmaceuticals 10 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of RLAY or TARS? 97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 4.3% of Relay Therapeutics shares are held by insiders. Comparatively, 8.3% of Tarsus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer RLAY or TARS? Relay Therapeutics received 10 more outperform votes than Tarsus Pharmaceuticals when rated by MarketBeat users. Likewise, 69.66% of users gave Relay Therapeutics an outperform vote while only 68.42% of users gave Tarsus Pharmaceuticals an outperform vote. CompanyUnderperformOutperformRelay TherapeuticsOutperform Votes6269.66% Underperform Votes2730.34% Tarsus PharmaceuticalsOutperform Votes5268.42% Underperform Votes2431.58% SummaryRelay Therapeutics beats Tarsus Pharmaceuticals on 11 of the 19 factors compared between the two stocks. Get Relay Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RLAY vs. The Competition Export to ExcelMetricRelay TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$557.73M$2.95B$5.53B$7.93BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-1.2630.0722.5118.54Price / Sales55.73494.82397.62103.30Price / CashN/A168.6838.1834.62Price / Book0.563.176.734.25Net Income-$341.97M-$72.35M$3.22B$248.18M7 Day Performance2.81%2.14%1.38%1.03%1 Month Performance32.13%5.67%2.79%2.70%1 Year Performance-53.53%-23.57%15.41%4.05% Relay Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RLAYRelay Therapeutics1.9283 of 5 stars$3.29-1.2%$18.36+458.2%-50.6%$557.73M$10.01M-1.26330Upcoming EarningsTARSTarsus Pharmaceuticals2.0699 of 5 stars$48.51-1.5%$63.67+31.2%+54.8%$1.86B$182.95M-12.7350Earnings ReportUpcoming EarningsNews CoveragePositive NewsGMTXGemini TherapeuticsN/A$42.17+2.8%N/A+73.2%$1.83BN/A-42.1730BEAMBeam Therapeutics3.0729 of 5 stars$18.24+7.3%$49.45+171.1%-8.8%$1.82B$63.52M-10.36510Upcoming EarningsShort Interest ↑High Trading VolumeNAMSNewAmsterdam Pharma3.1618 of 5 stars$16.26-0.5%$43.33+166.5%-8.8%$1.79B$45.56M-6.254Positive NewsKYMRKymera Therapeutics2.001 of 5 stars$27.16+4.6%$56.36+107.5%-4.7%$1.76B$47.07M-11.61170News CoverageBLTEBelite Bio2.9721 of 5 stars$54.69-3.0%$96.67+76.8%+50.9%$1.74BN/A-49.2710News CoveragePositive NewsBHCBausch Health Companies4.1713 of 5 stars$4.72-7.5%$7.17+51.8%-39.5%$1.74B$9.63B-39.3319,900Analyst UpgradeJANXJanux Therapeutics3.0204 of 5 stars$29.30-1.3%$95.25+225.1%-44.9%$1.73B$10.59M-25.0430Upcoming EarningsNews CoveragePositive NewsGap DownAAPGAscentage Pharma Group InternationalN/A$19.12+2.1%N/AN/A$1.66B$980.65M0.00600Gap DownARWRArrowhead Pharmaceuticals3.6117 of 5 stars$12.08+7.5%$41.44+243.1%-39.4%$1.66B$2.50M-2.34400Positive News Related Companies and Tools Related Companies TARS Alternatives GMTX Alternatives BEAM Alternatives NAMS Alternatives KYMR Alternatives BLTE Alternatives BHC Alternatives JANX Alternatives AAPG Alternatives ARWR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RLAY) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relay Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RLAY Stock Free RLAY Stock Alerts